Sernova (TSE:SVA) Releases Earnings Results, Beats Expectations By $0.01 EPS

Sernova (TSE:SVA) released its quarterly earnings results on Monday. The company reported C($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.01, reports.

Sernova Price Performance

TSE SVA opened at C$0.25 on Thursday. The firm has a market capitalization of C$79.48 million, a price-to-earnings ratio of -1.88 and a beta of 1.38. The company has a debt-to-equity ratio of 16.55, a current ratio of 0.62 and a quick ratio of 18.11. The company has a 50 day simple moving average of C$0.26 and a 200-day simple moving average of C$0.36. Sernova has a 52-week low of C$0.20 and a 52-week high of C$0.83.

Insider Buying and Selling at Sernova

In related news, Director Steven Sangha sold 930,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders purchased 379,600 shares of company stock valued at $97,671 in the last quarter. Company insiders own 12.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on SVA shares. Ventum Cap Mkts raised shares of Sernova to a “strong-buy” rating in a research report on Thursday, September 12th. Leede Financial lowered their price objective on shares of Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating on the stock in a research report on Friday, September 13th. Finally, Ventum Financial cut their target price on shares of Sernova from C$3.00 to C$2.50 and set a “buy” rating on the stock in a research note on Friday, September 13th.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.